Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Brain organoids may guide Alzheimer’s diagnosis and treatment

Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients with Alzheimer's disease may be used to evaluate how certain patients with the neurodegenerative condition may respond to drugs commonly prescribed to treat psychiatric symptoms of the disorder.

20 Apr 2026

Serotonin may worsen tinnitus symptoms, mice study finds

The same neurotransmitter commonly leveraged to relieve symptoms of depression and anxiety also may exacerbate a vexing condition known as tinnitus, according to new research published in the Proceedings of the National Academy of Sciences.

20 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Higher mortality risk in IBS patients using antidepressants

Research indicates that antidepressant use in IBS is linked to a 35% higher risk of all-cause mortality, highlighting safety issues with long-term treatment.

13 Apr 2026

When omega-3 may help mental health and when they may not

Investigating omega-3 fatty acids, this review highlights their impact on mental health, inflammation, and the potential for therapeutic use in disorders.

10 Apr 2026

Long-term study links common IBS medications to mortality risk

A large, long-term study led by Cedars-Sinai Health Sciences University investigators suggests that some medications commonly prescribed to treat irritable bowel syndrome (IBS)-including antidepressants-may be associated with a small but measurable increase in the risk of death.

8 Apr 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

NOX-1 identified as key molecular target to prolong ketamine's antidepressant effects

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers rapid relief, its antidepressant effects fade within a few weeks.

30 Mar 2026

Chronotherapy offers new hope for timing pain relief to match body cycles

Time plays a key role in our perception of pain and administering pain relief and medication for chronic pain-related depression may be more effective at certain times of day, UCL and University of Toronto researchers say.

23 Mar 2026

Psychiatrists’ use of biomarkers could open a new window into mental health diagnoses

Amanda Miller was 30 and pregnant with her second child in Hershey, Pennsylvania, when she developed depression.

17 Mar 2026

ADHD prescriptions surged during the COVID-19 pandemic

A study reveals COVID-19 reshaped stimulant prescribing patterns in Ontario, highlighting increased ADHD diagnoses and concerns over treatment appropriateness.

11 Mar 2026

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026

Berries, apples, and citrus linked to greater happiness and optimism

A study links flavonoid-rich diets to sustained happiness and optimism, highlighting the bidirectional relationship between diet and psychological well-being.

5 Mar 2026

Standard doses of antidepressants during pregnancy appear to be safe, study suggests

Using a standard dose of antidepressants during pregnancy appears to be safe for the baby, suggests new research from the University of Oslo and Akershus University Hospital.

24 Feb 2026

Five sessions a day TMS approach may reduce depression symptoms in one week

For the many patients with depression who haven't found relief through medication, transcranial magnetic stimulation (TMS) - a noninvasive therapy that uses magnetic pulses to stimulate specific areas of the brain - has become an increasingly important treatment option.

23 Feb 2026

As more Americans embrace anxiety treatment, MAHA derides medications

After a grueling year of chemotherapy, surgery, and radiation to treat breast cancer, Sadia Zapp was anxious — not the manageable hum that had long been part of her life, but something deeper, more distracting.

23 Feb 2026

Exercise pills could offer new hope for depression treatment

We all know the feeling: the mental clarity that comes after a good run or a heavy workout. Science backs this up, even showing that for non-severe depression, exercise can be just as effective as antidepressants or therapy.

19 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Short-duration psychedelic therapy shows promise for major depression treatment

A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.

17 Feb 2026

SSRI use during pregnancy linked to gestational diabetes risk and early adaptation problems in newborns

An international team of researchers has found that the use of SSRI antidepressants during pregnancy is associated with an increased risk of gestational diabetes and early adaptation problems in newborns, even after taking maternal depression into account.

13 Feb 2026